We used this assay to screen a custom si RNA library targeting 940 genes linked to the LOAD-gene network.
This approach has helped reveal interactions between TREM2, CD33, and other genes implicated in LOAD, and represents a general method for using RNAi to reveal regulatory nodes in disease networks defined by human genetics and genomics.
Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing EXPLORING NEW TARGETS & PATHWAYS Identifying Regulatory Interactions Among Genes Linked to Alzheimer’s Disease Michael Ollmann, Ph.
D., Team Leader, RNAi Screening, National Center for Advancing Translational Sciences, National Institutes of Health There is a tremendous need for biologically relevant cancer models that can accurately predict the clinical efficaciousness of various drugs.
Here we describe the development of In vitro model platforms that are designed to be biologically relevant to fill a critical gap between the cellular and animal model domains and offer the opportunity to study compounds that are therapeutically attractive.
The development of 3D models used in high-throughput screening to address relevant questions in cancer biology will be discussed.
Development of Physiologically Relevant Assay Platforms to Probe Various Disease Pathologies Madhu Lal-Nag, Ph.
Advances in genomic technologies have helped reveal the network of genes involved in late-onset Alzheimer’s disease (LOAD).
High-throughput sequencing to catalog human genetic variation, coupled with population studies to correlate genotype with disease risk, has greatly expanded the list of genes linked to LOAD.Genome-wide screens using RNA interference have proven powerful in elucidating components of functionally related pathways and have therefore become integral for the development of new and improved therapeutic targets.This article provides an overview of many of the systems biology approaches taken, using RNA interference, in order to demonstrate how it may be used today for drug discovery and tomorrow as a targeted therapy.In that regard, a combined approach can be more informative than any one approach alone.This talk will attempt to highlight the need for a flexible approach towards functional genomics screening, and the contexts in which certain platforms may be more appropriate. High-Throughput RNAi Screening for Immune Modulatory Ligands on Tumor Cells Philipp Beckhove. D., Head, Translational Immunology Division, German Cancer Research Center Heidelberg; Director, Regensburg Center for Interventional Immunology, University of Regensburg Immune checkpoint inhibition has lately revolutionized cancer therapy.